Quotes 5-day view Delayed Nasdaq
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
30.08(c)
30.8(c)
29.34(c)
27.94(c)
28.68(c)
Last
3 052 003
2 985 962
1 621 746
1 799 979
1 703 112
Volume
-3.28% +2.39% -4.74% -4.77% +2.65% Change
Sales 2021
102 M - -
Net income 2021
-800 M - -
Net cash position 2021
668 M - -
P/E ratio 2021
-2,45x
Yield 2021
-
Sales 2022
233 M - -
Net income 2022
-724 M - -
Net cash position 2022
517 M - -
P/E ratio 2022
-2,92x
Yield 2022
-
Capitalization
1 926 M 1 926 M -
EV / Sales 2021
12,4x
EV / Sales 2022
6,05x
Nbr of Employees
1 201
Free-Float
98,4%
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat...
Notations Surperformance© of bluebird bio, Inc.
Trading Rating : Investor Rating :
All news about BLUEBIRD BIO, INC.
03/04 INVESTOR ACTION NOTICE : The Schall Law Firm Announces the Filing of a Class Act..PR
03/03 SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..PR
03/02 BLUEBIRD BIO : Morgan Stanley Adjusts bluebird bio PT to $45 From $50, Maintain..MT
03/01 BLUEBIRD BIO : ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird b..PR
02/27 BREAKING NOTICE : Rosen, a Globally Recognized Law Firm, Encourages bluebird bio..BU
02/26 BLUEBIRD BIO : to Present at Cowen Health Care ConferenceBU
02/24 BRISTOL MYERS SQUIBB : Bluebird Bio Phase 2 Study of Multiple Myeloma Treatment..MT
02/24 BLUEBIRD BIO : The New England Journal of Medicine Publishes Results from Pivot..BU
02/24 GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Clas..BU
02/24 BLUEBIRD BIO : Barclays Adjusts bluebird bio PT to $27 From $31, Maintains Equa..MT
02/24 BLUE SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio..BU
02/23 BLUEBIRD : 4Q Earnings SnapshotAQ
02/23 BLUEBIRD BIO : Management's Discussion and Analysis of Financial Condition and ..AQ
02/23 BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Financial S..AQ
02/23 BLUEBIRD BIO : Earnings Flash (BLUE) BLUEBIRD BIO Reports Q4 Revenue $10.7M, vs..MT
News in other languages on BLUEBIRD BIO, INC.
Analyst Recommendations on BLUEBIRD BIO, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BLUEBIRD BIO, INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
24
Average target price
44,28 $
Last Close Price
28,68 $
Spread / Highest target
200%
Spread / Average Target
54,4%
Spread / Lowest Target
-9,34%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
